AHA 2014

Area: Cardiology

Location: Chicago, United States

Date: November 15 to November 19

Description:

Scientific Sessions 2014.


Search in Scientific Content:
Date
Filters:
Young wome
8:04

Young women with stable CHD are more likely to develop myocardial ischemia with mental stress than men of similar age

Presenter: Viola Vaccarino
Cardiology
Asthma may
7:07

Asthma may significantly raise risk of cardiovascular events

Presenter: Matthew C. Tattersall
Cardiology
Active ast
7:25

Active asthma may significantly raise risk of heart attack

Presenter: Duk Won Bang
Cardiology
Secondhand
6:21

Secondhand marijuana smoke may damage blood vessels as much as tobacco smoke

Presenter: Matthew Springer
Cardiology
Increased ...
9:06

Increased Risk of Ischemic Events Upon Discontinuation of Prasugrel After 12 or 30 Months of Therapy Following Placement of the Taxus Liberté Paclitaxel-Eluting Coronary Stent

Presenter: Kirk Garratt
Cardiology
Randomized
7:28

Randomized, Double Blind Trial of 6 vs. 12 Months of Dual Antiplatelet Therapy After DES-Implantation (ISAR-SAFE)

Presenter: Stephanie Schulz Schupke
Cardiology
Is 6 Month
9:41

Is 6 Months DAPT Post Coronary Stenting Non Inferior to 24 Months? The Italic/Italic+ Randomized Trial. Results of the One Year Primary Endpoint (ITALIC)

Presenter: Martine Gilard
Cardiology
Risk and B
17:55

Risk and Benefit of Prolonged Dual Antiplatelet Therapy After Drug-eluting Coronary Stents: Primary Endpoint Results from the Dual Antiplatelet Therapy Study (DAPT Study)

Presenter: Laura Mauri
Cardiology
Low-Dose A
8:12

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Patients with Multiple Atherosclerotic Risk Factors: A Randomized Controlled Trial

Presenter: Kazuyuki Shimada
Cardiology
Screening
7:18

Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using Coronary CT Angiography: Primary Results of FACTOR- 64, a Randomized Controlled Trial (FaCTor-64)

Presenter: Joseph Muhlstein
Cardiology
ODYSSEY AL
7:40

ODYSSEY ALTERNATIVE: Efficacy and Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients with Statin Intolerance as Defined by a Placebo Runin and Statin Rechallenge Arm

Presenter: Patrick Moriarty
Cardiology
IMPROVE IT
10:18

IMPROVE IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes

Presenter: Christopher Paul Cannon
Cardiology
Low-Dose A...
21:44

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Elderly Patients with Multiple Atherosclerotic Risk Factors: A Randomized Controlled Trial (Lecture, Discussant, Panel Discussion – Long Version)

Presenter: Kazuyuki Shimada
Cardiology
Screening ...
17:15

Screening For Asymptomatic Obstructive Coronary Artery Disease Among High-Risk Diabetic Patients Using Coronary CT Angiography: Primary Results of FACTOR- 64, a Randomized Controlled Trial (Lecture, Discussant, Panel Discussion – Long Version)

Presenter: Joseph Muhlstein
Cardiology
ODYSSEY AL
20:55

ODYSSEY ALTERNATIVE: Efficacy and Safety of the Proprotein Convertase Subtilisin/kexin Type 9 Monoclonal Antibody, Alirocumab, versus Ezetimibe, in Patients with Statin Intolerance as Defined by a Placebo Runin and Statin Rechallenge Arm

Presenter: Patrick Moriarty
Cardiology
IMPROVE IT...
30:12

IMPROVE IT Trial: A Comparison of Ezetimibe/Simvastatin versus Simvastatin Monotherapy on Cardiovascular Outcomes After Acute Coronary Syndromes (Lecture, Discussant, Panel Discussion – Long Version)

Presenter: Christopher Paul Cannon
Cardiology
Effect of ...
5:47

Effect of Naturally Random Allocation to Lower Low-Density Lipoprotein Cholesterol on the Risk of Coronary Heart Disease Mediated by Polymorphisms in NPC1L1, HMGCR, or Both: A 2 × 2 Factorial Mendelian Randomization Study

Presenter: Brian A. Ference
Cardiology
Gilles Mon
10:58

Gilles Montalescot's perspective on new findings of DAPT

Presenter: Gilles Montalescot
Cardiology
FDA's stat
3:49

FDA's statement on new DAPT safety and efficacy findings by Mary Ross Southworth

Presenter: Mary Ross Southworth
Cardiology
FDA's pers
3:36

FDA's perspective on new DAPT safety findings

Presenter: Bram Zuckerman
Cardiology
The result
4:45

The results of the Japanese Primary Prevention Program

Presenter: Dorairaj Prabhakaran
Cardiology
Karol Wats
3:52

Karol Watson on the ODYSSEY ALTERNATIVE trial results

Presenter: Karol Watson
Cardiology
Donald Llo
3:09

Donald Lloyd-Jones on the IMPROVE-IT trial results

Presenter: Donald Lloyd-Jones
Cardiology
Pamela Dou
3:50

Pamela Douglas on the FACTOR-64 trial results

Presenter: Pamela S. Douglas
Cardiology
Karol Wats
4:29

Karol Watson on the IMPROVE-IT trial results

Presenter: Karol Watson
Cardiology
Neil Stone
5:28

Neil Stone on the IMPROVE-IT trial results

Presenter: Neil J. Stone
Cardiology
Gordon Tom
7:07

Gordon Tomaselli on AHA2014 novelties in the treatment of atrial fibrillation

Presenter: Gordon Tomaselli
Cardiology
John A Ele
4:09

John A Elefteriades on Atenolol vs. Losartan in Marfan Syndrome trial results

Presenter: John A Elefteriades
Cardiology
Euan Ashle
6:00

Euan Ashley on the results of INHERIT Trial

Presenter: Euan Ashley
Cardiology
Dhruv Kazi
6:28

Dhruv Kazi on the increasing incidence of infective endocarditis in England

Presenter: Dhruv Kazi
Cardiology
David Adam
5:08

David Adams on the surgical treatment of moderate ischemic mitral regurgitation

Presenter: David Adams
Cardiology
Robert Har
9:46

Robert Harrington's Summary on the AHA2014 Scientific Sessions Highlights

Presenter: Robert Harrington
Cardiology

ESC Rome 2016

2016-08-27 - 2016-08-31
Rome, Italy

AHA 2015

2015-11-07 - 2015-11-11
Orlando, United States

ESC 2015

2015-08-29 - 2015-09-02
London, United Kingdom

CE Summit 2014

2014-12-06 - 2014-12-07
Ljubljana, Slovenia

ESC 2014

2014-08-30 - 2014-09-03
Barcelona, Spain